Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.

Lipum AB

A unique way to treat chronic inflammatory diseases.

Lipum is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late pre-clinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores several other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden, and its unique approach has attracted international attention, including a major European Commission Horizon 2020 grant.

Lipum has identified a unique target molecule of the immune system to develop safer and more efficacious treatment of chronic inflammatory diseases and satisfy unmet medical needs for millions of people.

Dr Einar Pontén, CEO
An exciting development based on a novel target molecule and convincing pre-clinical data.

Fakta om Lipum AB

Lipum AB
Tvistevägen 48C
907 36 Umeå

Västerbottens län
Umeå kommun

Telefon: +46 90 340 34 30

VAT nummer: SE556813599901

Anställda: 5

Se hemsidan


Einar Pontén
Telefon: +46 903403430

Sänd till en kollega